On June 8, Abivax S.A. declined 5.32% in regular trading, trading at $97.13/share, with trading volume of approximately $54.04 million.

The decline reflects persistent investor anxiety over safety signals from the company's Phase 3 ABTECT maintenance trial for obefazimod in moderately to severely active ulcerative colitis. While the trial met its primary endpoint with placebo-adjusted clinical remission rates of 39.3% (25mg) and 40.3% (50mg) at week 44 — described by the company as the highest placebo-adjusted remission rates in any UC maintenance Phase 3 study — the 50mg group reported cases of prostate cancer, breast cancer, colonic dysplasia, and multiple non-melanoma skin cancers.

The stock had previously plunged over 40% intraday on June 2 when the data was first released, before partially recovering. Wedbush Securities has noted that obefazimod faces elevated risk of a black box warning due to malignancy cases, while Jefferies analysts indicated the cancer-related adverse events will continue to suppress market sentiment and the drug's commercialization outlook. Morgan Stanley lowered its price target from $145 to $132 while maintaining an overweight rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)